Ophtec receives CE Mark for Artiplus IOL; a new solution for young Presbyopes

A big plus in refractive surgery

The international clinical study in 9 countries for Artiplus demonstrated excellent and consistent results. This innovative lens design, built upon Ophtec's trusted Artiflex platform, incorporates a patented multi-segmented optic (CTF technology) which generates multiple elongated focal points for clear vision and smooth transitions at all distances.

"We are thrilled to introduce Artiplus as a new treatment option for presbyopia," said Tiago Guerreiro, Global Product Manager at Ophtec. "Many people in their 40s are frustrated with the limitations of reading glasses or are struggling with multifocal glasses. Traditional presbyopia treatments, like laser surgery, are not sufficient for many patients. Artiplus offers a compelling solution for those seeking to regain high quality of vision at all distances."

Professor Dr. José Güell, lead investigator of the international clinical trial, emphasized the exceptional results: "The one-year follow-up data for uncorrected distance, intermediate, and near visual acuity were extraordinarily good. In my experience with Artiplus, the results have been extremely consistent."

Artiplus was already available in South Korea, showcasing the same strong results in the field as in the clinical trial. Early adopter Dr. Chin Young Im highlighted the lens's versatility: "I have successfully implanted Artiplus in pseudophakic patients, and they are all very pleased with the outcomes."

"Artiplus is a big plus in refractive surgery," stated Remko Bos, Marketing Manager at Ophtec. "The clinical trial results exceeded our expectations, demonstrating an exceptional range of focus (VA ≤ 0.10 LogMAR across defocus levels from +0.50 to -3.00 D). Moreover, all patients were satisfied with the procedure and the current uncorrected vision. With this CE approval, we are excited to offer this promising new treatment option to patients worldwide."